Recent updates on CAR T clinical trials for multiple myeloma

被引：0
|
作者：
Quande Lin
Juanjuan Zhao
Yongping Song
Delong Liu
机构：
[1] The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,
来源：
Molecular Cancer | / 18卷
关键词：
B cell maturation antigen; BCMA; Chimeric antigen receptor; CAR T; Multiple myeloma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM. CD19- targeted CAR T cells in conjunction with autologous stem cell transplantation also showed activity in RRMM. Dual- target CAR T cells are in clinical trials for RRMM. This review summarized the recent updates of ongoing CAR T clinical trials for multiple myeloma.
引用
收藏
相关论文
共 50 条
  • [1] Recent updates on CAR T clinical trials for multiple myeloma
    Lin, Quande
    Zhao, Juanjuan
    Song, Yongping
    Liu, Delong
    [J]. MOLECULAR CANCER, 2019, 18 (01)
  • [2] Updates in CAR T Therapy for Multiple Myeloma
    Lonial, Sagar
    [J]. ONCOLOGY-NEW YORK, 2020, 34 (07): : 283 - 286
  • [3] Updates on CAR T cell therapy in multiple myeloma
    Nasiri, Fatemeh
    Asaadi, Yasaman
    Mirzadeh, Farzaneh
    Abdolahi, Shahrokh
    Molaei, Sedigheh
    Gavgani, Somayeh Piri
    Rahbarizadeh, Fatemeh
    [J]. BIOMARKER RESEARCH, 2024, 12 (01)
  • [4] Clinical experience of CAR T cells for multiple myeloma
    Simmons, Gary L.
    Satta, Toshihisa
    Puglianini, Omar Castaneda
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (03)
  • [5] Characteristics of Clinical Trials for Multiple Myeloma and CAR-T Cell Therapy: A Cross Sectional Analysis
    Togra, Akanksha
    Sheth, Neil
    Vahora, Ilma
    Maharaj, Satish
    Deoker, Abhizith
    [J]. BLOOD, 2023, 142
  • [6] Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
    Dejenie, Tadesse Asmamaw
    Medhin, Markeshaw Tiruneh G.
    Terefe, Gashaw Dessie
    Admasu, Fitalew Tadele
    Tesega, Wondwossen Wale
    Abebe, Endeshaw Chekol
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [7] Multiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging
    Mosebach, Jennifer
    Thierjung, Heidi
    Schlemmer, Heinz-Peter
    Delorme, Stefan
    [J]. ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2019, 191 (11): : 998 - 1009
  • [8] Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
    Martino, Massimo
    Rossi, Marco
    Ferreri, Anna
    Loteta, Barbara
    Morabito, Antonella
    Moscato, Tiziana
    Console, Giuseppe
    Innao, Vanessa
    Naso, Virginia
    Provenzano, Pasquale Fabio
    Recchia, Anna Grazia
    Gentile, Massimo
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (08) : 665 - 684
  • [9] CAR T cell therapy for multiple myeloma
    Barranco, Caroline
    [J]. NATURE CANCER, 2023, 4 (12) : 1644 - 1644
  • [10] Future of CAR T cells in multiple myeloma
    Wudhikarn, Kitsada
    Mailankody, Sham
    Smith, Eric L.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 272 - 279
12345